RadNet (RDNT) Stock Price, News & Analysis

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RDNT shares.
View RDNT analyst ratings or view top-rated stocks.

3 brokerages have issued twelve-month target prices for RadNet's shares. Their RDNT share price targets range from $48.00 to $58.00. On average, they anticipate the company's stock price to reach $53.67 in the next year. This suggests a possible upside of 12.2% from the stock's current price.
View analysts price targets for RDNT or view top-rated stocks among Wall Street analysts.

RadNet's stock was trading at $34.77 on January 1st, 2024. Since then, RDNT stock has increased by 37.5% and is now trading at $47.81.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RDNT earnings forecast.

RadNet, Inc. (NASDAQ:RDNT) posted its quarterly earnings data on Friday, March, 1st. The medical research company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.09. The medical research company had revenue of $420.38 million for the quarter, compared to the consensus estimate of $410.11 million. RadNet had a trailing twelve-month return on equity of 4.72% and a net margin of 0.19%. The firm's quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.11 EPS.

ETFs with the largest weight of RadNet (NASDAQ:RDNT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Services ETF (XHS), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Invesco S&P SmallCap Momentum ETF (XSMO), First Trust Small Cap Growth AlphaDEX Fund (FYC) and SPDR S&P 600 Small Cap Growth ETF (SLYG).iShares U.S. Healthcare Providers ETF (IHF).

RadNet updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion.

174 employees have rated RadNet Chief Executive Officer Howard G. Berger on Glassdoor.com. Howard G. Berger has an approval rating of 45% among the company's employees. This puts Howard G. Berger in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), OPKO Health (OPK), Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Pfizer (PFE) and AT&T (T).

RadNet's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Contravisory Investment Management Inc. (0.01%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Christine Nayoma Gordon, David L Swartz, Lawrence L Levitt, Michael N Murdock, Norman R Hames and Ruth Louisa Villigerwilson.
View institutional ownership trends.

Shares of RDNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.